Molecular biology of high-grade gliomas: What should the clinician know?

Chinese Journal of Cancer

Volumn 33, Issue 1, 2014, Pages 4-7

  Hofer, Silvia ^a   Rushing, Elisabeth ^a   Preusser, Matthias ^b   Marosi, Christine ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

1p 19q; Diagnosis; EGFRvIII; High grade glioma; IDH 1 2; MGMT; Molecular biology; Prediction; Prognosis

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; PROTEIN P53; TEMOZOLOMIDE;

CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; GENOTYPE; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; METHYLATION; MOLECULAR BIOLOGY; POINT MUTATION; POLYMERASE CHAIN REACTION; REVIEW; WORLD HEALTH ORGANIZATION;

AGED; BRAIN NEOPLASMS; CHROMOSOME DELETION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; NEOPLASM GRADING; OLIGODENDROGLIOMA; POINT MUTATION; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 84891711258     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10218     Document Type: Review

References (25)

1. Paravati AJ, Heron DE, Landsittel D, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group- Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol, 2011,104:339-349.
2. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol, 2006,24:2563-2569.
3. Yang P, Wang Y, Peng X, et al. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol, 2013,113:259-266.
4. Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 2007,114:97-109.
5. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol, 2013,31:337-343.
6. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol, 2013,31:344-350.
7. Weller M, Stupp R, Hegi M, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol, 2012,14 (Suppl 4):iv100-iv108.
8. Radiation therapy with or without temozolomide in treating patients with anaplastic glioma. ClinicalTrials.gov Identifier:NCT00626990. Verified May 2011 by National Cancer Institute (NCI). ClinicalTrials. gov processed this record on December 01, 2013. http://clinicaltrials.gov/ct2/show/NCT00626990?term=NCT00626990&rank=1.
9. Radiation therapy with concomitant and adjuvant temozolomide or radiation therapy with adjuvant PCV or temozolomide alone in treating patients with anaplastic glioma. Clinical Trials.gov identifier: NCT00887146. Verified November 2013 by Alliance for Clinical Trials in Oncology. ClinicalTrials.gov processed this record on December 01, 2013. http://clinicaltrials.gov/ct2/show/NCT00887146?term=NCT00887146.&rank=1.
10. Hofer S, Lassman AB. Molecular markers in gliomas: impact for the clinician. Targ Oncol, 2010,5:201-210.
11. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005,352:997-1003.
12. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012,13:707-715
13. Malmström A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol, 2012,13:916-926.
14. Zou P, Xu H, Chen P, et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One, 2013, 8:e68782.
15. Capper D, Weissert S, Balss J et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol, 2010,20:245-254.
16. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J, 2013,280:5350-5370.
17. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol, 2010,28:4722-4729
18. Phase III study of rindopepimut/GM-CSF in patients with newly diagnosed glioblastoma. Clinical Trials.gov identifier: NCT01480479. Verified November 2013 by Celldex Therapeutics. ClinicalTrials.gov processed this record on December 01, 2013. http://clinicaltrialsgov/ct2/show/NCT01480479?term=NCT01480479+.&rank=1
19. Kloosterhof NK, Bralten LB, Dubbink HJ, et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol, 2011,12:83-91
20. Malzkorn B, Wolter M, Riemenschneider MJ, et al. Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. Brain Pathol, 2011,21:619-632.
21. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol, 2013,37:685-698.
22. Nicolaides TP, Li H, Solomon DA, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 2011,17:7595-7604.
23. Bloch O, Crane CA, Kaur R, et al. Gliomas promote immuno- suppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res, 2013,19:3165-3175.
24. Illhan-Mutlu A, Wagner L, Preusser M. Circulating biomarkers of CNS tumors: an update. Biomark Med, 2013,7:267-285.
25. Salkeni MA, Zarzour A, Ansay TY, et al. Detection of EGFRvII mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol, 2013,115:27-35.